- Invega (paliperidone) is an atypical antipsychotic medication that is derived from the active metabolite of risperidone.
- It is approved by the Food and Drug Administration (FDA), the Canadian Therapeutic Products Directorate (TPD) and the European Medicines Evaluation Agency (EMEA) for the treatment of schizophrenia. It has not been approved for the treatment of bipolar disorder; however, it is often prescribed off-label for acute mania.
- Invega is an extended-release formulation, so you only have to take it once a day, usually in the morning. It can be taken with or without food, but should be swallowed whole. Do not divide these pills.
- The most common side effects are restlessness and extrapyramidal symptoms.
- Invega carries the same box warning as all atypical antipsychotics regarding the increased risk of death in elderly patients with dementia-related psychosis.
- Be sure that your prescribing physician is aware that you are taking Invega or Risperdal (risperidone) before adding either medication to your regimen. The use of these two drugs together has not been studied.
- You may see what looks like an undigested pill in your stool while taking this medication. This is normal. It is actually only the shell of the pill, which does not absorb during digestion because of the extended-release design.
- This drug has not been tested or approved for the treatment of children or adolescents under the age of 18.
EMEA. (2008, September 6). EPARs for Authorised Medicinal Products for Human Use: Invega
FDA. (2007, March 30). Patient Information Sheet Paliperidone (Marketed as Invega).
Health Canada. (2008, April 4). Summary Basis of Decision (SBD) INVEGA.
Ortho-McNeil-Janssen Pharmaceuticals, Inc. (2008, October 16). Invega (Paliperidone)